Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan

Keiichi Ito, Shuji Mikami, Katsunori Tatsugami, Naoya Masumori, Nobuo Shinohara, Tsunenori Kondo, Shotaro Nakanishi, Yoji Nagashima, Masatoshi Eto, Tomomi Kamba, Naoto Kuroda, Yoshihiko Tomita, Hideyasu Matsuyama, Tetsuro Onishi, Tomoyasu Tsushima, Hayakazu Nakazawa, Mototsugu Oya, Seiichiro Ozono, Seiji Naito, Tomohiko Asano

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Standard treatments have not been established in metastatic papillary renal-cell carcinoma (PRCC). We aimed to investigate treatment outcomes in patients with mPRCC. Patients and Methods: This study included 51 patients who were diagnosed with PRCC at 14 institutions. Pathologic slides were reviewed by pathologists. The associations between clinical factors and overall survival (OS) were analyzed. Results: Final pathologic diagnoses could be determined in 50 patients. Thirty-five tumors were diagnosed as PRCC (type 2 PRCC, 91.4%), and 15 were diagnosed as other histologic types. Targeted therapies (TTs) were provided to 25 mPRCC patients. Patients treated with TT survived significantly longer than those treated before the era of TT (median OS, 22.5 vs. 6.3 months; P = .0035). Median OS of patients who experienced stable disease for ≥ 9 months using single TT was 43.1 months. Patients treated with a tyrosine kinase inhibitor (TKI) as first-line TT survived longer after TT initiation than those treated with an mTOR inhibitor (median, 22.4 vs. 11.7 months; P = .2684). Patients treated with TKIs in both first- and second-line settings had significantly better survival after TT initiation than those treated with a TKI in one therapy line and an mTOR inhibitor in the other (31.4 vs. 12.9 months, P = .0172). Patients treated with a TKI as second-line TT survived significantly longer after second-line TT initiation than did those treated with an mTOR inhibitor (16.2 vs. 7.4 months, P = .0016). Conclusion: Prognoses of patients with mPRCC were improved by TT, and TKIs appeared to be the treatment of choice in both the first- and second-line settings. We aimed to investigate treatment outcomes in patients with metastatic papillary renal-cell carcinoma. Patients treated with targeted therapy (TT) survived significantly longer than those treated before the era of TT. Patients treated with tyrosine kinase inhibitors (TKIs) in both first- and second-line settings had significantly better survival after initiation of TT than those treated with a TKI in one therapy line and an mTOR inhibitor in the other.

Original languageEnglish
Pages (from-to)e1201-e1214
JournalClinical Genitourinary Cancer
Volume16
Issue number6
DOIs
Publication statusPublished - Dec 2018

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan'. Together they form a unique fingerprint.

  • Cite this

    Ito, K., Mikami, S., Tatsugami, K., Masumori, N., Shinohara, N., Kondo, T., Nakanishi, S., Nagashima, Y., Eto, M., Kamba, T., Kuroda, N., Tomita, Y., Matsuyama, H., Onishi, T., Tsushima, T., Nakazawa, H., Oya, M., Ozono, S., Naito, S., & Asano, T. (2018). Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan. Clinical Genitourinary Cancer, 16(6), e1201-e1214. https://doi.org/10.1016/j.clgc.2018.07.028